ArticleRenal failure2026
Differential serum dynamics of apelin, elabela, and angiotensinogen in CKD and haemodialysis: insights into peptide modulation across the dialysis procedure.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence suggests that apelinergic peptides and components of the renin-angiotensin system (RAS) are key regulators of cardiovascular homeostasis and fluid balance, both disrupted in chronic kidney disease (CKD). This study aimed to assess serum levels of apelin, elabela, and angiotensinogen across the CKD spectrum and evaluate their acute modulation during a single hemodialysis (HD) session. Serum samples from healthy controls (
methodsApelin levels were significantly lower in CKD compared to controls but elevated in HD patients prior to treatment. No significant change occurred post-dialysis, suggesting minimal dialytic clearance or rapid compensation. In contrast, elabela was markedly reduced pre-dialysis but increased post-dialysis in most patients, indicating dynamic regulation or partial removal. Angiotensinogen was elevated before HD and declined significantly after.
resultsCorrelations with estimated glomerular filtration rate (eGFR) were modest and not significant after adjusting for group membership, indicating that group stratification primarily drove associations. Linear regression showed that reductions in angiotensinogen correlated inversely with changes in apelin, while higher uric acid and urea predicted post-dialysis increases in elabela and suppression of angiotensinogen, respectively.
conclusionThese findings highlight distinct, peptide-specific responses to HD and support a context-dependent interplay between uremic burden, peptide systems, and dialysis-induced shifts. Apelinergic and RAS peptides may represent promising biomarkers of intradialytic cardiovascular modulation. Further studies are warranted to explore their prognostic and therapeutic implications in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.